Follow
Roland Preece
Roland Preece
Verified email at ucl.ac.uk
Title
Cited by
Cited by
Year
Long terminal repeat CRISPR-CAR-coupled “universal” T cells mediate potent anti-leukemic effects
C Georgiadis, R Preece, L Nickolay, A Etuk, A Petrova, D Ladon, A Danyi, ...
Molecular Therapy 26 (5), 1215-1227, 2018
1332018
Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia
R Chiesa, C Georgiadis, F Syed, H Zhan, A Etuk, SA Gkazi, R Preece, ...
New England Journal of Medicine 389 (10), 899-910, 2023
1302023
Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia
G Ottaviano, C Georgiadis, SA Gkazi, F Syed, H Zhan, A Etuk, R Preece, ...
Science translational medicine 14 (668), eabq3010, 2022
992022
TCRαβ/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy
J Rasaiyaah, C Georgiadis, R Preece, U Mock, W Qasim
JCI insight 3 (13), 2018
972018
Base-edited CAR T cells for combinational therapy against T cell malignancies
C Georgiadis, J Rasaiyaah, SA Gkazi, R Preece, A Etuk, A Christi, ...
Leukemia 35 (12), 3466-3481, 2021
892021
CRISPR-mediated base conversion allows discriminatory depletion of endogenous T cell receptors for enhanced synthetic immunity
R Preece, A Pavesi, SA Gkazi, KA Stegmann, C Georgiadis, ZM Tan, ...
Molecular Therapy-Methods & Clinical Development 19, 149-161, 2020
182020
‘Mini’U6 Pol III promoter exhibits nucleosome redundancy and supports multiplexed coupling of CRISPR/Cas9 effects
R Preece, C Georgiadis, SA Gkazi, A Etuk, A Christi, W Qasim
Gene therapy 27 (9), 451-458, 2020
162020
Tvt CAR7: phase 1 clinical trial of base-edited universal” CAR7 T cells for paediatric Relapsed/Refractory T-ALL
R Chiesa, C Georgiadis, G Ottaviano, F Syed, T Braybrook, A Etuk, ...
Blood 140 (Supplement 1), 4579-4580, 2022
132022
Universal'Fratricide-Resistant CAR T Cells Against T Cell Leukemia Generated By Coupled & Uncoupled Deamination Mediated Base Editing
C Georgiadis, J Rasaiyaah, SA Gkazi, R Preece, A Etuk, A Christi, ...
Blood 134, 3219, 2019
42019
Emerging CRISPR/Cas9 applications for T-cell gene editing
R Preece, C Georgiadis
Emerging Topics in Life Sciences 3 (3), 261-275, 2019
32019
Therapeutic cells
W Qasim, C Georgiadis, R Preece, U Mock, L Nickolay
US Patent App. 16/470,933, 2020
12020
CD62L-selected umbilical cord blood universal CAR T cells
C Georgiadis, L Bor, F Syed, H Zhan, SA Gkazi, A Etuk, ...
bioRxiv, 2024.01. 18.576145, 2024
2024
Investigation of chimeric Fc gamma RIIIa receptor (cFcR) engineered'Universal'T cells in combination with anti-CD20 monoclonal antibody
A Etuk, C Georgiadis, R Preece, W Qasim
HUMAN GENE THERAPY 33 (23-24), A125-A125, 2022
2022
Base edited" universal''CAR T cells against childhood AML
R Kadirkamanathan, C Georgiadis, A Etuk, T Braybrook, R Preece, ...
HUMAN GENE THERAPY 33 (23-24), A124-A125, 2022
2022
Comparison of cytidine deaminase base editors for multiplexed editing of T cells
H Aldahshan, R Preece, H Brezovjakova, C Georgiadis, W Qasim
HUMAN GENE THERAPY 33 (23-24), A131-A131, 2022
2022
CRISPR-coupled CAR engineering of universal donor T cells for paediatric B-ALL
C Georgiadis, G Ottaviano, SA Gkazi, F Syed, H Zhan, A Etuk, R Preece, ...
HUMAN GENE THERAPY 33 (23-24), A14-A14, 2022
2022
Minimal promoter
W Qasim, C Georgiadis, R Preece, SA Gkazi
US Patent App. 17/593,184, 2022
2022
Enhancing Strategies for CRISPR/Cas9 Based T cell Engineering
R Preece
UCL (University College London), 2020
2020
Multiplexed Cytidine Deamination Enables Generation of Fratricide-Resistant'Universal T v T'Chimeric Antigen Receptor Cell Therapy
C Georgiadis, J Rasaiyaah, SA Gkazi, R Preece, A Etuk, A Christi, ...
MOLECULAR THERAPY 28 (4), 212-212, 2020
2020
Recombinant T Cell Receptor Immunity Against Hepatitis B Surface Antigen Following Disruptive Base Editing of Endogenous T Cell Receptor
SA Gkazi, R Preece, A Pavesi, K Stegmann, C Georgiadis, D Tan, JY Aw, ...
MOLECULAR THERAPY 28 (4), 340-340, 2020
2020
The system can't perform the operation now. Try again later.
Articles 1–20